Table 4.

Logistic regression comparing hospitalisation rates between patients with rheumatic immune-mediated inflammatory diseases and healthy controls, and different treatment groups

	Hospitalisation rate		Crude model			Adjusted model
	No.	%	OR	95% CI	P value	OR	95% CI	P value
Healthy controls*	1/134	0.7	1.00	N.A.		1.00	N.A.
Rheumatic patients	23/347	7	9.37	(1.25 to 70.10)	0.029	7.33	(0.96 to 55.77)	0.055
No treatment with csDMARDs*	12/160	8	1.00	N.A.		1.00	N.A.
Treatment with any csDMARD	10/186	5	0.77	(0.33 to 1.80)	0.55	0.83	(0.36 to 2.28)	0.91
Methotrexate	8/137	6	–	–	–	1.44	(0.39 to 5.31)	0.59
No treatment with bDMARDs*	14/217	6	1.00	N.A.		1.00	N.A.
Treatment with any bDMARD	8/129	6	0.90	(0.37 to 2.17)	0.81	1.00	(0.37 to 2.66)	1.00
TNF inhibitor	4/105	4	–	–	–	0.40	(0.11 to 1.45)	0.16
B-cell targeting therapy	3/7	4	–	–	–	14.62	(2.31 to 92.39)	0.004†
No treatment with prednisone*	18/304	6	1.00	N.A.		1.00	N.A.
Prednisone	2/12	17	2.74	(0.50 to 15.03)	0.25	1.73	(0.22 to 13.83)	0.61

Data are ORs with 95% CIs in parentheses, and p values. All adjusted ORs are adjusted for age, sex and presence of cardiovascular or chronic pulmonary diseases. Adjusted ORs for treatment groups are also adjusted for concomitant treatment with other immunosuppressive drugs.

Bold=p<0.050.

*Reference group.

†Below the Benjamini threshold.

bDMARDs, biological DMARDs; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; N.A., not available; TNF, tumour necrosis factor.